Supreme Court decision signals likely end to Allergan sovereign immunity gambit

A lower court's ruling that a sovereign entity cannot assert immunity to shield a patent from inter partes review (IPR) will stand, as the U.S. Supreme Court rejected a petition from Allergan and

Read the full 336 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE